| | |
| Clinical data | |
|---|---|
| Other names | 6-Bromo-MDA; 6-Br-MDA; 6-Bromo-3,4-methylenedioxyamphetamine; 2-Bromo-4,5-methylenedioxyamphetamine; 2-Bromo-4,5-MDA; 2-Br-4,5-MDA |
| Routes of administration | Oral [1] |
| Drug class | Psychoactive drug; Stimulant |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown [1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider |
|
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H17BrNO2 |
| Molar mass | 275.166 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
6-Bromo-MDA, also known as 6-bromo-3,4-methylenedioxyamphetamine or as 2-bromo-4,5-methylenedioxyamphetamine (2-bromo-4,5-MDA), is a psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to 3,4-methylenedioxyamphetamine (MDA). [1] [2] It is the 6-bromo derivative of MDA. [1] In his book PiHKAL (Phenethylamines I Have Known and Loved), Alexander Shulgin lists 6-bromo-MDA's dose as 350 mg orally and its duration as unknown. [1] 6-Bromo-MDA has been reported to produce amphetamine-like effects with no other details provided. [1] However, Daniel Trachsel reported that 6-bromo-MDA was inactive at doses of up to 350 mg. [2] The chemical synthesis of 6-bromo-MDA has been described. [1] 6-Bromo-MDA was first described in the scientific literature by Silvia Sepaveda and colleagues by 1972. [2] [3] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991. [1]
| | This psychoactive drug-related article is a stub. You can help Wikipedia by adding missing information. |